Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial

Lignende værker

• One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
  af: Pratley, R, et al.
  Udgivet: (2011)
• GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
  af: Gilbert, Matthew P., et al.
  Udgivet: (2020)
• First GLP-1 analog liraglutide: the result of clinical trails on efficacy
  af: Alexander Sergeevich Ametov, et al.
  Udgivet: (2011-12-01)
• Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus
  af: Kim, Sun Woo
  Udgivet: (2010)
• The effect of liraglutide, a GLP-1 analog, on indomethacin-induced gastric ulcers in diabetic rats
  af: Huseyin Emre Arslan, et al.
  Udgivet: (2025-09-01)